Patent 7501121 was granted and assigned to Wyeth on March, 2009 by the United States Patent and Trademark Office.
Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.